Timing can be everything when it comes to a cancer diagnosis - the sooner it's found, the more treatable it is. But when and how often should someone get screened?
A growing number of educational, interactive tools known as "decision aids" - such as videodiscs, audiotapes, workbooks and pamphlets - are intended to supplement patient-doctor discussions on the pros and cons of timing, methods and frequency for different types of cancer screening.
Study: Postcode Inequality for Cancer Diagnosis 'Costs Lives'
If they were diagnosed at the same stage as those who lived in affluent areas, hundreds of women with breast cancer living in England's most deprived areas would have better survival rates.
Advertisement
A University of Michigan study found that despite strong recommendations from the medical community to use these aids to help patients make more well-informed decisions, there is lack of evidence on whether they work - which may lead to fewer doctors using them.
"We continue to see more cancer screening options and also conflicting recommendations on whether to get screened, which method to use and how often it should be done," says lead author Masahito Jimbo, M.D., Ph.D., M.P.H., associate professor in family medicine and urology at the U-M Medical School.
![Study Shows How Breast Implants Can Delay Cancer Diagnosis]( "Study Shows How Breast Implants Can Delay Cancer Diagnosis")
A thorough probe into the potential health risks of breast implants has been urgently called for, after a study showed how this type of cosmetic surgery may delay cancer diagnosis in women.
"Our goal was to determine whether decision aids could potentially lead to better shared decision-making regarding screening between the patient and the clinician. There is evidence that decision aids are fairly effective in improving patient knowledge but we found that they may not be used as well and effectively as they could be."
The study appears in CA: A Cancer Journal for Clinicians, a medical journal published for the American Cancer Society.
Decision aids are delivered as self-administered or practitioner administered tools designed to help patients understand the disease, associated tests and treatments and the risks versus benefits of different types of screening. They are designed to help address such issues as whether to get a stool blood test versus a colonoscopy for colon cancer screening or whether women under the age of 50 should get screened for breast cancer at all.
Researchers reviewed 73 decision aids for breast, cervical, colon and prostate cancers. Just half of the decision aids, 36, were evaluated for subsequent screening behavior. Only a quarter of the decision aids, 18, had been assessed for their effect on shared decision making. Little information was available on the feasibility and outcomes of integrating decision aids into actual practice.
"These decision aids are designed as tools to improve communication between patients and clinicians, so it's surprising that there is so little data to support claims that they improve shared decision making," Jimbo says.
With the push towards more sophisticated electronic health records, decision aids may become more available to patients looking for additional guidance on health decisions, authors note.
Certain screening options also continue to be debated among the medical community. The U.S. Preventive Services Task Force, for example, recommended against routine screening for prostate cancer, while other guidelines encourage doctors and patients to weight the risks and benefits. Decision aids may assist patients and doctors work through those conflicting recommendations together.
"Do decision aids help improve communication between a patient and physician and can that improved communication lead to better outcomes - those are the broader questions we need to answer," Jimbo says.
"There is also some disconnect between how decision aids can help if they're actually applied and physicians actually using them. As we see an increased emphasis on the importance of shared decision making between patients and doctors, we need to better understand what the most valuable tools are in aiding this goal."
Source: Eurekalert
Study Shows How Breast Implants Can Delay Cancer Diagnosis
A thorough probe into the potential health risks of breast implants has been urgently called for, after a study showed how this type of cosmetic surgery may delay cancer diagnosis in women.
Advertisement
"Our goal was to determine whether decision aids could potentially lead to better shared decision-making regarding screening between the patient and the clinician. There is evidence that decision aids are fairly effective in improving patient knowledge but we found that they may not be used as well and effectively as they could be."
The study appears in CA: A Cancer Journal for Clinicians, a medical journal published for the American Cancer Society.
Decision aids are delivered as self-administered or practitioner administered tools designed to help patients understand the disease, associated tests and treatments and the risks versus benefits of different types of screening. They are designed to help address such issues as whether to get a stool blood test versus a colonoscopy for colon cancer screening or whether women under the age of 50 should get screened for breast cancer at all.
Researchers reviewed 73 decision aids for breast, cervical, colon and prostate cancers. Just half of the decision aids, 36, were evaluated for subsequent screening behavior. Only a quarter of the decision aids, 18, had been assessed for their effect on shared decision making. Little information was available on the feasibility and outcomes of integrating decision aids into actual practice.
"These decision aids are designed as tools to improve communication between patients and clinicians, so it's surprising that there is so little data to support claims that they improve shared decision making," Jimbo says.
With the push towards more sophisticated electronic health records, decision aids may become more available to patients looking for additional guidance on health decisions, authors note.
Certain screening options also continue to be debated among the medical community. The U.S. Preventive Services Task Force, for example, recommended against routine screening for prostate cancer, while other guidelines encourage doctors and patients to weight the risks and benefits. Decision aids may assist patients and doctors work through those conflicting recommendations together.
"Do decision aids help improve communication between a patient and physician and can that improved communication lead to better outcomes - those are the broader questions we need to answer," Jimbo says.
"There is also some disconnect between how decision aids can help if they're actually applied and physicians actually using them. As we see an increased emphasis on the importance of shared decision making between patients and doctors, we need to better understand what the most valuable tools are in aiding this goal."
Source: Eurekalert
Breast Cancer Diagnosis and Treatment Brought to Underserved Area of Uganda By New Breast Imaging Algorithm
In an underserved region of Uganda, radiologists are a step closer to implementing a program for diagnosing and treating women with palpable breast masses.
Advertisement
 African Americans Experience Longer Delay Between Prostate Cancer Diagnosis and Treatment: StudyAccording to a recent study African American men on average wait a week longer than their Caucasian counterparts between the initial diagnosis of prostate cancer and treatment. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.